Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct‐acting anti‐virals
-
- Yuki Tahata
- Suita Japan
-
- Ryotaro Sakamori
- Suita Japan
-
- Ryoko Yamada
- Suita Japan
-
- Takahiro Kodama
- Suita Japan
-
- Hayato Hikita
- Suita Japan
-
- Hideki Hagiwara
- Amagasaki Japan
-
- Yasuharu Imai
- Ikeda Japan
-
- Naoki Hiramatsu
- Sakai Japan
-
- Shinji Tamura
- Minoh Japan
-
- Keiji Yamamoto
- Tanabe Japan
-
- Masahide Oshita
- Osaka Japan
-
- Kazuyoshi Ohkawa
- Osaka Japan
-
- Taizo Hijioka
- Kawachinagano Japan
-
- Hiroyuki Fukui
- Yao Japan
-
- Toshifumi Ito
- Osaka Japan
-
- Yoshinori Doi
- Osaka Japan
-
- Yukinori Yamada
- Kaizuka Japan
-
- Takayuki Yakushijin
- Osaka Japan
-
- Yuichi Yoshida
- Suita Japan
-
- Tomohide Tatsumi
- Suita Japan
-
- Tetsuo Takehara
- Suita Japan
抄録
<jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Several factors associated with hepatocellular carcinoma (HCC) occurrence after sustained virological response (SVR) in patients with hepatitis C have been reported. However, few validation studies have been performed in the era of direct‐acting anti‐virals (DAAs).</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To develop a prediction model for HCC occurrence after DAA‐mediated SVR and validate its usefulness.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We analysed 2209 patients with SVR and without a history of HCC who initiated DAA treatment at 24 Japanese hospitals. These patients were divided into a training set (1473 patients) and a validation set (736 patients).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In the training set, multivariate Cox proportional hazards analysis showed that the baseline BMI (≥25.0 kg/m<jats:sup>2</jats:sup>, <jats:italic>P</jats:italic> = 0.024), baseline fibrosis‐4 (FIB‐4) index (≥3.25, <jats:italic>P</jats:italic> = 0.001), albumin level at SVR (<4.0 g/dL, <jats:italic>P</jats:italic> = 0.010) and alpha‐foetoprotein level at SVR (≥5.0 ng/mL, <jats:italic>P</jats:italic> = 0.006) were significantly associated with HCC occurrence. We constructed a prediction model for HCC occurrence with these four factors (2 points were added for the FIB‐4 index, and 1 point was added for each of the other three factors). Receiver operating characteristics curve analysis identified a score of 2 as the optimal cut‐off value for the prediction model (divided into 0‐1 and 2‐5). In the validation set, the sensitivity and negative predictive value for HCC occurrence were 87.5% and 99.7%, respectively, at 2 years and 71.4% and 98.0%, respectively, at 3 years.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>A prediction model combining these four factors contributes to an efficient surveillance strategy for HCC occurrence after DAA‐mediated SVR.</jats:p></jats:sec>
収録刊行物
-
- Alimentary Pharmacology & Therapeutics
-
Alimentary Pharmacology & Therapeutics 54 (10), 1340-1349, 2021-10-07
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360857593790131200
-
- ISSN
- 13652036
- 02692813
-
- データソース種別
-
- Crossref
- KAKEN